HEALWELL More than Doubles YoY Adjusted EBITDA in Q3-2026 and Improves YTD Operating Cashflow by $26 Million

HEALWELL grows revenue and cash flow but remains deeply unprofitable despite operational gains.

What the company is saying

HEALWELL AI Inc. presents its Q3 2026 results as evidence of successful execution on its AI-driven healthcare strategy, emphasizing recurring revenue growth and operational milestones. CEO James Lee highlights the expansion of AI deployments, citing agreements with Converge Health Iowa and New Brunswick as proof of commercial momentum and cross-selling potential. The company stresses improvements in operational efficiency, with CFO Anthony Lam pointing to a $26.0 million year-over-year improvement in operating cash flow and ongoing compliance with credit covenants. Management frames the $17.7 million SpaceX investment as a source of future liquidity, expecting realization within twelve months post-lockup expiry in February 2027. The narrative is reinforced by references to peer-reviewed research, industry awards, and product adoption metrics, such as WELLTRUST surpassing 100,000 patient consents and SMART Suite outperforming AI benchmarks. While the tone is confident and forward-looking, the company acknowledges that higher non-cash charges offset operational improvements, resulting in a flat net loss.

What the data suggests

Quarterly revenue from continuing operations increased 7% year-over-year to $32.6 million, with gross profit up 3% to $17.1 million and gross margin slipping from 54% to 52%. Adjusted EBITDA rose sharply to $1.6 million (up 144%), but the IFRS net loss from continuing operations remained at $16.0 million, unchanged from Q3 2025. Operating expenses fell to $23.3 million from $25.1 million, and cash flow from operating activities for the first nine months reached $5.9 million, a $26.0 million improvement. As of September 30, 2026, cash and equivalents stood at $14.9 million, with a $17.7 million short-term investment in SpaceX held via a private fund, subject to lock-up until February 2027. The Data Science & AI segment saw revenue drop to $1.5 million from $2.0 million, while Healthcare Software Subscription, Support and Maintenance revenue grew 10% to $22.4 million. The company’s operational claims about AI performance and partnership scale are not matched by detailed quantitative evidence in the release. The financial trajectory shows improving cash flow and operational efficiency, but persistent large net losses and reliance on non-operating asset value for future liquidity.

Analysis

The announcement presents a positive tone, highlighting revenue growth (+7%), gross profit increase (+3%), and a substantial improvement in adjusted EBITDA (+144%). These realised financial metrics are supported by detailed numerical disclosures, including cash flow and segment breakdowns. However, the company continues to report a significant net loss ($16.0 million, unchanged year-over-year), and some operational claims—such as the impact of AI deployments, peer-reviewed research outperformance, and major partnership agreements—lack detailed supporting data or external validation. Several forward-looking statements (e.g., expected recurring revenue from new agreements, anticipated monetization of the SpaceX investment) are present but are not the majority of key claims. The overall hype is moderate, as the narrative emphasizes awards, product superiority, and strategic milestones without always providing underlying quantitative evidence. The gap between narrative and evidence is most pronounced in claims about AI performance and partnership scale, which are asserted but not substantiated with granular data.

Risk flags

• ●HEALWELL continues to report substantial net losses, with Q3 2026 IFRS net loss from continuing operations at $16.0 million, unchanged year-over-year. Persistent losses raise questions about the path to profitability and the sustainability of operations without further capital or asset sales.
• ●The company’s $17.7 million indirect SpaceX investment is illiquid until at least February 2027 due to lock-up restrictions. Realization of this asset is subject to market conditions and successful fund distribution, introducing timing and execution risk for expected liquidity.
• ●Operational claims regarding AI performance, product adoption, and partnership scale are not substantiated with granular data or external validation. This gap between narrative and evidence increases the risk that projected commercial and clinical impact may not materialize as described.
• ●Segment revenue in Data Science & AI fell 22% year-over-year to $1.5 million, reflecting lower project-based life sciences revenue. This decline could signal challenges in diversifying revenue streams or maintaining growth outside the core Healthcare Software segment.
• ●While cash flow from operations improved, the company’s cash balance declined from $18.6 million at year-end 2025 to $14.9 million at September 30, 2026, and ongoing losses may pressure liquidity if operational improvements stall or asset monetization is delayed.

Bottom line

HEALWELL AI Inc. is growing its top line and improving operating cash flow, but remains far from profitability, posting a $16.0 million net loss in Q3 2026. The company’s financial disclosures are detailed, with clear period comparisons and segment breakdowns, but the positive narrative around AI deployments and industry accolades is not fully supported by quantitative evidence. The SpaceX investment offers potential future liquidity, but is locked up until at least February 2027 and subject to market and distribution risks. Investors should focus on whether HEALWELL can further reduce losses, convert operational momentum into sustained profitability, and successfully monetize its non-core assets. The key takeaway is that while operational and cash flow improvements are real, the business remains structurally loss-making and reliant on future asset sales to bolster its balance sheet.

Announcement summary

(TSX:AIDX) (OTCQX:HWAIF) HEALWELL AI Inc. announced its unaudited interim condensed consolidated financial results for the quarter and nine months ended September 30, 2026. The company reported quarterly revenue from continuing operations of $32.6 million in Q3-2026, a 7% increase from $30.4 million in Q3-2025. Gross profit for Q3-2026 was $17.1 million, up 3% from $16.5 million in Q3-2025, with a gross margin of 52% compared to 54% in the prior year. Adjusted EBITDA for Q3-2026 was $1.6 million, a 144% increase from $0.7 million in Q3-2025. IFRS net loss from continuing operations for Q3-2026 was $16.0 million, unchanged from the previous year, as a $2.3 million improvement in loss from operations was offset by higher non-cash charges. As of September 30, 2026, HEALWELL had $14.9 million in cash and cash equivalents and a $17.7 million short-term investment representing its indirect interest in SpaceX. Data Science & AI segment revenue was $1.5 million in Q3-2026, down from $2.0 million in Q3-2025. Subscription, Support and Maintenance revenue in the Healthcare Software segment grew 10% compared to Q3-2025. For the nine months ended September 30, 2026, revenue was $98.7 million, up from $71.6 million in the prior year, and gross profit was $54.5 million, up from $39.6 million. Operating expenses for Q3-2026 totaled $23.3 million, down from $25.1 million in Q3-2025. The company generated $5.9 million in cash flow from operating activities during the first nine months of 2026, a $26.0 million improvement over the prior-year period. The fair value of the company's indirect interest in SpaceX was $17.7 million as of September 30, 2026, compared to a carrying value of approximately CAD$4.6 million as of March 31, 2026. The investment in SpaceX is held indirectly through a private fund and is subject to lock-up restrictions expected to expire in February 2027. The company expects to realize the investment within twelve months through a distribution. Business highlights included a multi-million-dollar, multi-year agreement with Converge Health Iowa to deploy DARWEN™-powered SMART Search and SMART Summary across Iowa's statewide HIE infrastructure, and the deployment of SMART Summary in New Brunswick through Intrahealth, making the solution available to more than 400 clinicians. WELLTRUST™, a WELL-managed network using HEALWELL's DARWEN™ AI, surpassed 100,000 patient consents since its launch in February 2026. Peer-reviewed research showed DARWEN™-powered SMART Suite clinical summaries outperformed benchmarks for OpenAI's GPT, DeepSeek, and Llama, with up to 43% improvement and nearly 50% higher treatment-plan accuracy than a leading general-purpose AI model. SMART Patient ID identified more than 4,100 heart failure patients not receiving guideline-directed medical therapy. On August 19, 2026, HEALWELL's subsidiary Pentavere Research Group (now HEALWELL DARWEN Inc.) was nominated for the 2026 International Prix Galien Award in the Best Startup category, after winning the 2024 Prix Galien USA Award for Best Digital Health Startup. On October 6, 2026, peer-reviewed research found that MyHealthNB, built on VeroSource technology, was associated with significant improvements in patient empowerment and healthcare engagement. On October 15, 2026, HEALWELL was named to TIME's World's Top HealthTech Companies of 2026 in the AI & Data Analytics category and announced 12 scientific abstracts and presentations at 8 international conferences in the fall. The company will hold a conference call and webcast to discuss its financial results on November 10, 2026, hosted by CEO James Lee, President Dr. Alexander Dobranowski, and CFO Anthony Lam.

Disagree with this article?